Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|October 11, 2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerMartin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterMartin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitorsJia Liu, Malinda Itchins, Adnan Nagrial, et al.
Future Oncology (London, England)|February 15, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancerMarina C Garassino, Luis Paz-Ares, Rina Hui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE StudyPeter Fox, Rosemary L Balleine, Clara Lee, et al.
The Lancet. Oncology|November 14, 2017
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trialJulie R Brahmer, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.
The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
The Lancet. Oncology|October 12, 2019
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 studyRina Hui, Mustafa Özgüroğlu, Augusto Villegas, et al.
JTO Clinical and Research Reports|September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
Pageof 9